{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:19:47Z","timestamp":1789129187867,"version":"build-2803163510"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Diffuse large B-cell lymphoma (DLBCL) is treated with an expanding range of antibody- and cell-based therapies, yet macrophage phagocytosis checkpoints are still often discussed one molecule at a time. Here, we ask how far the evidence for each major axis has actually progressed in DLBCL immunotherapy. We considered five areas of support: lymphoma protein-level evidence, antibody-dependent cellular phagocytosis (ADCP),\n                    <jats:italic>in vivo<\/jats:italic>\n                    lymphoma data, clinical lymphoma evidence, and biomarker or predictive relevance. CD47\/SIRPalpha remains the reference point because it has the broadest mechanistic, lymphoma, and clinical support. Major histocompatibility complex class I (MHC-I)\/leukocyte immunoglobulin-like receptor B1 (LILRB1) and CD39\/CD73-adenosine signaling have meaningful lymphoma-related functional evidence but remain less mature clinically. CD24\/Siglec-10 is still best regarded as candidate\/emerging. CD200\/CD200R sits at a different stage: its myeloid biology, receptor structure, and Dok2-RasGAP signaling make it a credible candidate, but a direct DLBCL experiment showing restoration of anti-CD20 ADCP after pathway blockade is still lacking. We also consider how these pathways may be shaped by Fc receptor competence, spatial tumor-macrophage contact, anti-CD19 therapy, bispecific antibodies, and CAR-T-cell therapy. The purpose of the framework is practical: to separate what is already supported in lymphoma from what still needs to be tested before clinical claims are made.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1933140","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:15:16Z","timestamp":1789125316000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200"],"prefix":"10.3389","volume":"16","author":[{"given":"Shasha","family":"Qi","sequence":"first","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Guizhou University of Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Deng","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Guizhou Medical University","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Guizhou University of Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Guizhou University of Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Guizhou University of Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41408-019-0233-5","article-title":"Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma","volume":"9","author":"Wang","year":"2019","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70207","article-title":"Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up","volume":"9","author":"Thieblemont","year":"2025","journal-title":"HemaSphere"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70229","article-title":"2026 update on the management of diffuse large B-cell lymphoma","volume":"101","author":"Chong","year":"2026","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1182\/asheducation-2015.1.69","article-title":"Checkpoint blockade in lymphoma","volume":"2015","author":"Armand","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00620-6","article-title":"Clinical relevance of tumour-associated macrophages","volume":"19","author":"Pittet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.879713","article-title":"An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone","volume":"55","author":"Nam","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/s41467-024-46220-z","article-title":"Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02353-5","article-title":"Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma","volume":"57","author":"Dai","year":"2025","journal-title":"Nat Genet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284795","article-title":"Blockade of the CD47\/SIRPalpha checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab","volume":"109","author":"Biedermann","year":"2024","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell Malignancies","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fc gamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013277","article-title":"Magrolimab plus rituximab in relapsed\/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1\/2 trial","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.687","article-title":"A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha monoclonal antibody, in patients with relapsed\/refractory non-Hodgkin lymphoma","volume":"4","author":"Narkhede","year":"2023","journal-title":"EJHaem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286208","article-title":"Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study","volume":"110","author":"Kim","year":"2025","journal-title":"Haematologica"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1826","article-title":"A phase I trial of evorpacept, lenalidomide, and rituximab for patients with B-cell non-Hodgkin lymphoma","volume":"31","author":"Strati","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","article-title":"Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy","volume":"19","author":"Barkal","year":"2018","journal-title":"Nat Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.929339","article-title":"Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages","volume":"13","author":"Zeller","year":"2022","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01794-9","article-title":"Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma","volume":"37","author":"Casey","year":"2023","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0811-3","article-title":"Targeting an adenosine-mediated 'don't eat me signal' augments anti-lymphoma immunity by anti-CD20 monoclonal antibody","volume":"34","author":"Nakamura","year":"2020","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.266","article-title":"CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma","volume":"8","author":"Higashi","year":"2022","journal-title":"J Pathol Clin Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/682168","article-title":"CD200:CD200R-mediated regulation of immunity","volume":"2012","author":"Gorczynski","year":"2012","journal-title":"ISRN Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.6.3034","article-title":"Characterization of the CD200 receptor family in mice and humans and their interactions with CD200","volume":"171","author":"Wright","year":"2003","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.18632\/oncotarget.28354","article-title":"The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy","volume":"14","author":"Shao","year":"2023","journal-title":"Oncotarget"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(02)02223-8","article-title":"CD200 and membrane protein interactions in the control of myeloid cells","volume":"23","author":"Barclay","year":"2002","journal-title":"Trends Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.11.6786","article-title":"Molecular mechanisms of CD200 inhibition of mast cell activation","volume":"173","author":"Zhang","year":"2004","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5497.1768","article-title":"Down-regulation of the macrophage lineage through interaction with OX2 (CD200)","volume":"290","author":"Hoek","year":"2000","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/cyto.b.21128","article-title":"CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry","volume":"86","author":"Sandes","year":"2014","journal-title":"Cytometry B Clin Cytom"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425080","article-title":"The CD200 and CD200 receptor cell surface proteins interact through their N-terminal immunoglobulin-like domains","volume":"34","author":"Hatherley","year":"2004","journal-title":"Eur J Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901531","article-title":"Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells","volume":"183","author":"Mihrshahi","year":"2009","journal-title":"J Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1038\/s41467-021-22832-7","article-title":"CD200\u2013CD200R immune checkpoint engagement regulates ILC2 effector function and ameliorates lung inflammation in asthma","volume":"12","author":"Shafiei-Jahani","year":"2021","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/B978-0-12-800100-4.00005-2","article-title":"The CD200-CD200R1 inhibitory signaling pathway: immune regulation and host-pathogen interactions","volume":"121","author":"Vaine","year":"2014","journal-title":"Adv Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1038\/s41467-025-60456-3","article-title":"CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPalpha-CD47 to suppress tumor growth","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150750","article-title":"CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis","volume":"132","author":"Morgan","year":"2022","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient antitumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001802","article-title":"CD200 expression marks leukemia stem cells in human AML","volume":"4","author":"Ho","year":"2020","journal-title":"Blood Adv"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584427","article-title":"CD200 and chronic lymphocytic leukemia: biological and clinical relevance","volume":"10","author":"D'Arena","year":"2020","journal-title":"Front Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-029355","article-title":"CD200 is a new prognostic factor in multiple myeloma","volume":"108","author":"Moreaux","year":"2006","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1009686","article-title":"The role of CD200 in immunity to B cell lymphoma","volume":"88","author":"Wong","year":"2010","journal-title":"J Leukoc Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP38XRRUGSQOVC","article-title":"CD200 (OX-2 membrane glycoprotein) expression in B cell-derived neoplasms","volume":"134","author":"Dorfman","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.129","article-title":"Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers","volume":"25","author":"Dorfman","year":"2012","journal-title":"Mod Pathol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqad053","article-title":"Diagnostic utility of CD200 immunohistochemistry in distinguishing EBV-positive large B-cell lymphoma from classic Hodgkin lymphoma","volume":"160","author":"Batuello","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPBV9ELXC0ECVL","article-title":"Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging","volume":"142","author":"Challagundla","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPO2KKFHOEXNZF","article-title":"CD200 in high-grade lymphoma, chronic lymphocytic leukemia, and chronic lymphocytic leukemia-phenotype monoclonal B-cell lymphocytosis","volume":"144","author":"Sorigue","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2013.03.008","article-title":"Structures of CD200\/CD200 receptor family and implications for topology, regulation, and evolution","volume":"21","author":"Hatherley","year":"2013","journal-title":"Structure"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-504043","article-title":"Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab","volume":"122","author":"Golay","year":"2013","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1062192","article-title":"A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells","volume":"7","author":"Piccione","year":"2015","journal-title":"mAbs"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B71","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13059-016-1028-7","article-title":"Comprehensive analyses of tumor immunity: implications for cancer immunotherapy","volume":"17","author":"Li","year":"2016","journal-title":"Genome Biol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-0301-7_7","article-title":"Profiling cell type abundance and expression in bulk tissues with CIBERSORTx","volume":"2117","author":"Steen","year":"2020","journal-title":"Methods Mol Biol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0392-8","article-title":"Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas","volume":"38","author":"Moncada","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0105","article-title":"Eradication of canine diffuse large B-cell lymphoma in a murine xenograft model with CD47 blockade and anti-CD20","volume":"4","author":"Weiskopf","year":"2016","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1933140\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:15:18Z","timestamp":1789125318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1933140\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":77,"alternative-id":["10.3389\/fonc.2026.1933140"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1933140","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"1933140"}}